FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004163675> ?p ?o ?g. }

• W2004163675 endingPage "1056" @default.
• W2004163675 startingPage "1049" @default.
• W2004163675 abstract "Background: We retrospectively studied the effect of the lamivudine-induced reverse transcription mutation M184V on selection of thymidine analog mutations (TAMs) in HIV subtype C-infected children and on clinical outcome. Methods: We genotyped 135 blood samples from 55 children. TAMs accumulation, viral load and clinical outcome were compared in children maintained on zidovudine/stavudine + lamivudine + protease inhibitor/nonnucleoside reverse transcriptase inhibitor (PI/NNRTI) despite loss of viral suppression and in children treated with, or switched to, other nucleoside reverse transcriptase inhibitors (NRTIs). Drug susceptibility and replication capacity of selected samples were measured. Results: M184V developed in 18 of 22 of children who had received only zidovudine/stavudine + lamivudine + PI/NNRTI during a mean of 23.2 ± 3.2 months versus in 3 of 14 children treated with other drugs and/or having multiple regimen changes (P = 0.001). TAMs appeared, respectively, in 2 of 22 versus 12 of 14 (P < 0.0001). The 2 groups did not differ significantly in baseline HIV-RNA or CD4 count, sampling time, and follow-up period. In M184V-containing samples, we found large reductions in susceptibility to lamivudine and emtricitabine but not to other NRTIs. When T215Y was present without M184V, susceptibility to zidovudine was reduced 8-fold. When both M184V + T215Y occurred, susceptibility to zidovudine was substantially increased. Average inhibition concentration 50 values were similar to those documented in the Stanford database for subtype B HIV with these mutation patterns. Conclusions: Maintaining a thymidine analog + lamivudine-based regimen reduced accumulation of TAMs and increased zidovudine susceptibility. This is likely the result of an increased susceptibility to thymidine analog (zidovudine) in the context of M184V documented here for the first time in subtype C-infected children. This retrospective study supports the strategy of maintaining lamivudine-containing therapy in subtype C-infected children. This strategy may be beneficially applied in the treatment of children in Africa, where thymidine analog + lamivudine-based regimen became available recently but further options are limited." @default.
• W2004163675 created "2016-06-24" @default.
• W2004163675 creator A5001380464 @default.
• W2004163675 creator A5014470126 @default.
• W2004163675 creator A5027270066 @default.
• W2004163675 creator A5028059374 @default.
• W2004163675 creator A5029167470 @default.
• W2004163675 creator A5038605229 @default.
• W2004163675 creator A5044533190 @default.
• W2004163675 creator A5055049830 @default.
• W2004163675 creator A5068087274 @default.
• W2004163675 creator A5068462189 @default.
• W2004163675 creator A5081656135 @default.
• W2004163675 date "2006-11-01" @default.
• W2004163675 modified "2023-09-27" @default.
• W2004163675 title "Diminished Selection for Thymidine-Analog Mutations Associated With the Presence of M184V in Ethiopian Children Infected With HIV Subtype C Receiving Lamivudine-Containing Therapy" @default.
• W2004163675 cites W1965015272 @default.
• W2004163675 cites W1979033897 @default.
• W2004163675 cites W1995559092 @default.
• W2004163675 cites W2007968850 @default.
• W2004163675 cites W2026323517 @default.
• W2004163675 cites W2035938088 @default.
• W2004163675 cites W2043966364 @default.
• W2004163675 cites W2045953763 @default.
• W2004163675 cites W2047519516 @default.
• W2004163675 cites W2052200516 @default.
• W2004163675 cites W2062388675 @default.
• W2004163675 cites W2070137192 @default.
• W2004163675 cites W2083999199 @default.
• W2004163675 cites W2084273391 @default.
• W2004163675 cites W2096494921 @default.
• W2004163675 cites W2097059709 @default.
• W2004163675 cites W2097847166 @default.
• W2004163675 cites W2102133068 @default.
• W2004163675 cites W2103737563 @default.
• W2004163675 cites W2108259040 @default.
• W2004163675 cites W2108532941 @default.
• W2004163675 cites W2110192284 @default.
• W2004163675 cites W2120338717 @default.
• W2004163675 cites W2122858742 @default.
• W2004163675 cites W2124842769 @default.
• W2004163675 cites W2129933305 @default.
• W2004163675 cites W2148291080 @default.
• W2004163675 cites W2154901255 @default.
• W2004163675 cites W2317685534 @default.
• W2004163675 cites W2416259257 @default.
• W2004163675 cites W2419522998 @default.
• W2004163675 cites W347553799 @default.
• W2004163675 doi "https://doi.org/10.1097/01.inf.0000243211.36690.d5" @default.
• W2004163675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17072129" @default.
• W2004163675 hasPublicationYear "2006" @default.
• W2004163675 type Work @default.
• W2004163675 sameAs 2004163675 @default.
• W2004163675 citedByCount "18" @default.
• W2004163675 countsByYear W20041636752012 @default.
• W2004163675 countsByYear W20041636752013 @default.
• W2004163675 countsByYear W20041636752014 @default.
• W2004163675 countsByYear W20041636752015 @default.
• W2004163675 countsByYear W20041636752016 @default.
• W2004163675 countsByYear W20041636752017 @default.
• W2004163675 countsByYear W20041636752018 @default.
• W2004163675 countsByYear W20041636752019 @default.
• W2004163675 countsByYear W20041636752020 @default.
• W2004163675 countsByYear W20041636752021 @default.
• W2004163675 countsByYear W20041636752022 @default.
• W2004163675 crossrefType "journal-article" @default.
• W2004163675 hasAuthorship W2004163675A5001380464 @default.
• W2004163675 hasAuthorship W2004163675A5014470126 @default.
• W2004163675 hasAuthorship W2004163675A5027270066 @default.
• W2004163675 hasAuthorship W2004163675A5028059374 @default.
• W2004163675 hasAuthorship W2004163675A5029167470 @default.
• W2004163675 hasAuthorship W2004163675A5038605229 @default.
• W2004163675 hasAuthorship W2004163675A5044533190 @default.
• W2004163675 hasAuthorship W2004163675A5055049830 @default.
• W2004163675 hasAuthorship W2004163675A5068087274 @default.
• W2004163675 hasAuthorship W2004163675A5068462189 @default.
• W2004163675 hasAuthorship W2004163675A5081656135 @default.
• W2004163675 hasConcept C104317684 @default.
• W2004163675 hasConcept C126322002 @default.
• W2004163675 hasConcept C142462285 @default.
• W2004163675 hasConcept C156719811 @default.
• W2004163675 hasConcept C159047783 @default.
• W2004163675 hasConcept C182707283 @default.
• W2004163675 hasConcept C2522874641 @default.
• W2004163675 hasConcept C2776543447 @default.
• W2004163675 hasConcept C2777333352 @default.
• W2004163675 hasConcept C2777351918 @default.
• W2004163675 hasConcept C2777869810 @default.
• W2004163675 hasConcept C2779778239 @default.
• W2004163675 hasConcept C2779889181 @default.
• W2004163675 hasConcept C2780216070 @default.
• W2004163675 hasConcept C2780593183 @default.
• W2004163675 hasConcept C2780727368 @default.
• W2004163675 hasConcept C2781413609 @default.
• W2004163675 hasConcept C2993143319 @default.
• W2004163675 hasConcept C49105822 @default.
• W2004163675 hasConcept C54355233 @default.
• W2004163675 hasConcept C71924100 @default.

• next